U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C14H19NO2
Molecular Weight 233.3067
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHYLPHENIDATE

SMILES

COC(=O)[C@@]([H])(c1ccccc1)[C@]2([H])CCCCN2

InChI

InChIKey=DUGOZIWVEXMGBE-STQMWFEESA-N
InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m0/s1

HIDE SMILES / InChI
Methylphenidate is a CNS stimulant approved for the treatment of narcolepsy and attention deficit hyperactivity disorder. The drug is believed to bind the dopamine transporter in the presynaptic cell membrane, thereby blocking the reuptake of dopamine and causing an increase in extracellular dopamine levels.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q01959
Gene ID: 6531.0
Gene Symbol: SLC6A3
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RITALIN

Approved Use

Ritalin is indicated for the treatment of Attention Deficit Disorders and Narcolepsy.

Launch Date

-4.62153613E11
Primary
RITALIN

Approved Use

Ritalin is indicated for the treatment of Attention Deficit Disorders and Narcolepsy.

Launch Date

-4.62153613E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.7 ng/mL
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLPHENIDATE HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
41.8 ng × h/mL
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLPHENIDATE HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.5 h
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLPHENIDATE HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
90%
unknown, unknown
METHYLPHENIDATE HYDROCHLORIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
700 mg multiple, oral
Studied dose
unhealthy, 45 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 45 years
Sex: M
Population Size: 1
Sources:
Other AEs: Abuse...
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Other AEs: Hypertension, Tachycardia...
Other AEs:
Hypertension (grade 1)
Tachycardia (grade 1)
Confusion
Irritability
Agitation
Hallucinations
Sources:
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Disc. AE: Headache, Nausea...
AEs leading to
discontinuation/dose reduction:
Headache (1.6%)
Nausea (1.6%)
Hot flushes (1.6%)
Panic attack (1.6%)
Nausea (1.6%)
Vomiting (1.6%)
Dizziness (1.6%)
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Disc. AE: Fatigue, Lethargy...
AEs leading to
discontinuation/dose reduction:
Fatigue (1.5%)
Lethargy (1.5%)
Hypomania (1.5%)
Anger (1.5%)
Anxiety (1.5%)
Migraine (1.5%)
Depression (1.5%)
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
AEs

AEs

AESignificanceDosePopulation
Abuse
700 mg multiple, oral
Studied dose
unhealthy, 45 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 45 years
Sex: M
Population Size: 1
Sources:
Agitation
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Confusion
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Hallucinations
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Irritability
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Hypertension grade 1
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Tachycardia grade 1
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Dizziness 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Headache 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Hot flushes 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Nausea 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Nausea 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Panic attack 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Vomiting 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Anger 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Anxiety 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Depression 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Fatigue 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Hypomania 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Lethargy 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Migraine 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Cocaine-seeking produced by experimenter-administered drug injections: dose-effect relationships in rats.
1999 Dec
[Methylphenidate, tics and compulsions].
2000 Mar-Apr
Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine.
2001
Synthesis and pharmacology of site specific cocaine abuse treatment agents: a new synthetic methodology for methylphenidate analogs based on the Blaise reaction.
2001 Apr
Pharmacotherapeutic management of autism.
2001 Apr
Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder.
2001 Apr
Understanding Rx options for the youngest patients.
2001 Aug
Concerns about Ritalin.
2001 Aug
Rewarding properties of methylphenidate: sensitization by prior exposure to the drug and effects of dopamine D1- and D2-receptor antagonists.
2001 Aug
The use of baclofen in cluster headache.
2001 Feb
Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA.
2001 Feb
A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease.
2001 Feb 12
Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder.
2001 Feb 15
Treatment of attention-deficit hyperactivity disorder.
2001 Jan
Decreased level of EEG-vigilance in acute mania as a possible predictor for a rapid effect of methylphenidate: a case study.
2001 Jan
Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.
2001 Jan 15
[Methylphenidate therapy in 141 patients with hyperkinetic disorder or with pervasive developmental disorder and hyperkinesia].
2001 Jul
A comparison of the visual symptoms between ADD/ADHD and normal children.
2001 Jul
Stimulant drugs for severe hyperactivity in childhood.
2001 Jul
Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study.
2001 Jul-Aug
Comparison in symptoms between aged and younger patients with narcolepsy.
2001 Jun
The development of selective attention in children with attention deficit hyperactivity disorder.
2001 Jun
Attention deficit hyperactivity disorder and substance use disorders: Is there a causal link?
2001 Jun
Explosive outbursts associated with methylphenidate.
2001 Jun
Managing stimulant medication for attention-deficit/hyperactivity disorder.
2001 Jun
Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
2001 Jun
Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans.
2001 Jun
Practice parameters for the treatment of narcolepsy: an update for 2000.
2001 Jun 15
Commentary on Greene and Ablon: What does the MTA study tell us about effective psychosocial treatment for ADHD?
2001 Mar
Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review.
2001 Mar
ADHD treatment in the 21st century: pushing the envelope.
2001 Mar
Comprehensive versus matched psychosocial treatment in the MTA study: conceptual and empirical issues.
2001 Mar
Psychosocial treatment issues in the MTA: a reply to Greene and Ablon.
2001 Mar
Tailored psychosocial treatments for ADHD: the search for a good fit.
2001 Mar
What does the MTA study tell us about effective psychosocial treatment for ADHD?
2001 Mar
Case study: sexual hyperactivity treated with psychostimulants in familial male precocious puberty.
2001 Mar
[Problem in methylphenidate use for the treatment of attention deficit hyperactivity disorder in Japan].
2001 Mar
Near-fatal methylphenidate misuse.
2001 Mar
Addition of a 5-HT receptor agonist to methylphenidate potentiates the reduction of [123I]FP-CIT binding to dopamine transporters in rat frontal cortex and hippocampus.
2001 Mar 1
Evidence and belief in attention deficit hyperactivity disorder. Reintroduction of methylphenidate in Italy needs careful monitoring.
2001 Mar 3
[Neuropsychological follow-up of attention deficit/hyperactive disorder in adulthood before and after treatment with methylphenidate].
2001 May
Short-term cardiovascular effects of methylphenidate and adderall.
2001 May
Psychostimulants in preschool children with attention-deficit/hyperactivity disorder: clinical evidence from a developmental disorders institution.
2001 May
An auditable protocol for treating attention deficit/hyperactivity disorder.
2001 May
Methylphenidate sensitization is modulated by valproate.
2001 May 25
Gilles de la Tourette Syndrome.
2001 May-Jun
Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications.
2001 May-Jun
Depression with psychomotor retardation: diagnostic challenges and the use of psychostimulants.
2001 Spring
Methylphenidate augmentation of citalopram in elderly depressed patients.
2001 Summer
Patents

Sample Use Guides

Administer in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Average dosage is 20 to 30 mg daily. Some patients may require 40 to 60 mg daily. In children the starting dose is 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly.
Route of Administration: Oral
Murine neural stem cells were treated directly after seeding to the cover-slip using different concentration (0 nM, 1 nM, 10 nM, 100 nM) of methylphenidate. The drug was found to enhance neuronal differentiation and inhibit neural proliferation.
Name Type Language
METHYLPHENIDATE
HSDB   II   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
METHYLPHENIDATE [VANDF]
Common Name English
.ALPHA.-PHENYL-2-PIPERIDINEACETIC ACID METHYL ESTER
Systematic Name English
METHYLPHENIDATE [ORANGE BOOK]
Common Name English
METHYLPHENIDATE [INN]
Common Name English
METHYLPHENIDATE EXTENDED RELEASE
Common Name English
METHYLPHENIDATE [WHO-DD]
Common Name English
2-PIPERIDINEACETIC ACID, .ALPHA.-PHENYL-, METHYL ESTER
Common Name English
METHYLPHENIDATE [HSDB]
Common Name English
PRC-063
Common Name English
THREO-DL-METHYLPHENIDATE
Common Name English
COTEMPLA XR-ODT
Brand Name English
DAYTRANA
Brand Name English
METHYLPHENIDATE [MI]
Common Name English
METHYLPHENIDATE [MART.]
Common Name English
METHYLPHENIDATE [II]
Common Name English
METHYLPHENIDATE [USAN]
Common Name English
Classification Tree Code System Code
LIVERTOX 625
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
WHO-VATC QN06BA04
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
DEA NO. 1724
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
NDF-RT N0000175739
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
NCI_THESAURUS C47795
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
NDF-RT N0000175729
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
WHO-ATC N06BA04
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
Code System Code Type Description
INN
485
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
ChEMBL
CHEMBL796
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
DRUG CENTRAL
1767
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
DRUG BANK
DB00422
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
EVMPD
SUB08870MIG
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
FDA UNII
207ZZ9QZ49
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
RXCUI
6901
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY RxNorm
MESH
D008774
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
HSDB
113-45-1
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
ECHA (EC/EINECS)
204-028-6
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
EPA CompTox
113-45-1
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
CAS
20748-11-2
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
IUPHAR
7236
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
MERCK INDEX
M7453
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY Merck Index
LACTMED
Methylphenidate
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
WIKIPEDIA
METHYLPHENIDATE
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
NCI_THESAURUS
C62045
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
PRIMARY
CAS
113-45-1
Created by admin on Fri Jun 25 20:36:30 UTC 2021 , Edited by admin on Fri Jun 25 20:36:30 UTC 2021
NON-SPECIFIC STEREOCHEMISTRY